Table 7. High-Risk Disease (Stages IIIB, IVB)
| Chemotherapy (No. of Cycles)a | Radiation (Gy) | Stage | No. of Patients | Event-Free Survival (No. of Years of Follow-up) | Survival (No. of Years of Follow-up) |
| OEPA/OPPA (2) + COPP (4) [18] | IFRT (20–35) | IIEB, IIIEA/B, IIIB, IVA/B | 265 | 91% (5) | N/A |
| OEPA/OPPA (2) + COPDAC (4) [40] | IFRT (20–35) | IIEB, IIIEA/B, IIIB, IVA/B | 239 | 86.9% (5) | 94.9% (5) |
| ABVE-PC (3-5) [34] | IFRT (21) | IB, IIA, IIIA | 163 | 85% (5) | 95% (5) |
| BEACOPP (4); COPP/ABV (4) (RER; girls) [44] | None | IIB, IIIB, IV | 38 | 94% (5) | 97% (5) |
| BEACOPP (4); ABVD (2) (RER; boys) [44] | IFRT (21) | IIB, IIIB, IV | 34 | ||
| BEACOPP (8) (SER) [44] | IFRT (21) | IIB, IIIB, IV | 25 |
| E = extralymphatic; IFRT = involved-field radiation therapy; N/A = not applicable; No. = number; RER = rapid early response; SER = slow early response. | |||||
| aRefer to Table 4 for more information about the chemotherapy regimens. |
References
- Dörffel W, Lüders H, Rühl U, et al.: Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 215 (3): 139-45, 2003 May-Jun. [PUBMED Abstract]
- Schwartz CL, Constine LS, Villaluna D, et al.: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114 (10): 2051-9, 2009. [PUBMED Abstract]
- Mauz-Körholz C, Hasenclever D, Dörffel W, et al.: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28 (23): 3680-6, 2010. [PUBMED Abstract]
- Kelly KM, Sposto R, Hutchinson R, et al.: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 117 (9): 2596-603, 2011. [PUBMED Abstract]
